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Edited by Ivan SadowskiAbstract SRY-related HMG box-containing factor 10
(SOX10) is a transcription factor essential for neural crest devel-
opment and diﬀerentiation, and involved in Waardenburg syn-
drome type IV and PCWH syndrome. Here we show that the
SOX10 protein is modiﬁed by sumoylation, a highly dynamic
post-translational modiﬁcation that aﬀects stability, activity
and localisation of some speciﬁc transcription factors. Three
sumoylation consensus sites were found in the SOX10 protein,
all of them are functional and modulate SOX10 activity. Sumoy-
lation does not aﬀect SOX10 sub-cellular localisation, but re-
presses its transcriptional activity on two of its target genes,
GJB1 and MITF, and modulates its synergy with its cofactors
EGR2 and PAX3 on these promoters.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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SRY-related HMG box-containing factor 10 (SOX10) is a
member of the SOX family of transcription factors. It is ex-
pressed in the neural crest and its derivatives forming sensory,
sympathetic and enteric ganglia, melanocytes and glial cells of
the central and peripheral nervous system [1]. Heterozygous
SOX10 mutations cause Waardenburg syndrome type IV
(WS4), associatingHirschsprung disease (intestinal agangliono-
sis) andWaardenburg syndrome (pigmentation defects and sen-
sorineural deafness) [2]. Some WS4 patients also present with a
neurological phenotype, leading to PCWH syndrome (Periphe-
ral demyelinating neuropathy, Central dysmyelinating leukodys-
trophy, Waardenburg syndrome and Hirschsprung disease) [3].
Sumoylation is a post-translational modiﬁcation process
based on conjugation of a small peptide on a target protein
(for reviews, see [4,5]). Conjugation occurs in 4 steps: 1 – pro-
cessing; 2 – activation by an E1-type enzyme; 3 – conjugation
by an E2-type enzyme; 4 – ligation to the substrate by an E3-
type enzyme. Ubiquitin-conjugating enzyme 9 (UBC9) is theAbbreviations: SOX10, SRY-related HMG box-containing factor 10;
UBC9, ubiquitin-conjugating enzyme 9; SUMO, small ubiquitin-like
modiﬁer
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(SUMO) conjugation and it has been attributed the function
of substrate recognition. It is thus responsible for sumoylation
speciﬁcity, and it directly interacts with most target proteins.
Sumoylation occurs on a WKXE consensus site, where W
indicates a hydrophobic amino acid and K is the lysine of
attachment of SUMO. UBC9 is supposed to bind the target
protein on this consensus sequence. Although the global func-
tion of sumoylation is not perfectly identiﬁed yet, the conse-
quences of this modiﬁcation seem to be as diverse as its
targets. Among these, sumoylation appears to aﬀect stability,
activity and localisation of speciﬁc transcription factors, emerg-
ing as an important regulator of transcription function [6,7].
In an attempt to identify new SOX10 partners, we found
evidences that SOX10 directly interacts with UBC9, thus sug-
gesting that it may be sumoylated. We therefore studied this
post-translational modiﬁcation of the SOX10 protein and the
consequences on its function.2. Materials and methods
2.1. Two-hybrid screen
The bait plasmid pLEX-SOX10D TA contains the SOX10 coding se-
quence deleted from its transactivation domain (amino acids 376–466).
The prey library constructed from rat dorsal root ganglia mRNA was
a generous gift from Jaime Garcia-Anoveros (Chicago, USA). The bait
plasmid and prey library were introduced into the yeast strain L40 by
sequential transformation via the classical lithium acetate procedure.
His+ clones were selected on selective medium containing 5 mM 3-
AT (3-amino-1,2,4-triazole) and were tested for b-galactosidase activ-
ity. Prey clones were identiﬁed by direct sequencing of PCR-ampliﬁed
products obtained from yeast plasmids.
2.2. Plasmids
The pCMV5-SOX10-HA vector was kindly provided by Michael
Wegner (Erlangen, Germany). Mutations of sumoylation sites were
generated by replacing the lysine codon (AAG) of each site by an ala-
nine codon (GCG). The UBC9-V5 plasmid was generated by introduc-
ing the PCR-generated UBC9 coding sequence deleted from its stop
codon into the pcDNA3.1/V5-His-TOPO vector (Invitrogen).
The Myc-SUMO-1, -2 and -3 vectors were generated by introducing
the SUMO-1, -2, or -3 coding sequence in frame with the Myc tag in
the pCMV-Myc vector (Clontech) at its BglII cloning site. The
pECE-SOX10, pECE-EGR2, pECE-PAX3, pGL3-GJB1 and pGL3-
MITF vectors were previously described [8,9].
2.3. Liquid b-galactosidase activity assay
L40 yeast cells transformed with various baits and UBC9 or empty
prey vector were grown in selective liquid medium until OD600 reached
0.6–0.8. 1 ml of cell culture was pelleted and lysed using chloroform inblished by Elsevier B.V. All rights reserved.
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1 mM MgSO4, and 50 mM b-mercaptoethanol). Lysates were incu-
bated with 100 ll ONPG (ortho-nitrophenyl-b-D-galactopyranoside,
4 mg/ml) until a yellow colouration appeared. Enzymatic reactions
were stopped with 1 M Na2CO3. OD420 was measured and normalised
with OD600 measurement of the sample before reaction. Relative b-
galactosidase activity was determined for each bait tested by calculat-
ing the ratio: b-galactosidase activity (bait + UBC9)/b-galactosidase
activity (bait + empty prey vector).2.4. Cell culture and transient transfection
HeLa cells were grown in DMEM plus 10% foetal calf serum and
transfected using LipofectAMINE PLUS reagents (Invitrogen)
according to the manufacturer’s instructions. For immunoprecipita-
tion and EMSA experiments, cells were transfected in 100 mm plates
with 2 lg of each expression plasmid (IP) or with 5 lg of SOX10
plasmid (EMSA). For luciferase assays, cells were transfected in 6-
well plates with 0.350 lg of each eﬀector and reporter plasmid per
well, and with 50 or 200 ng of pCMVMyc-SUMO1 when indicated.
For immunoﬂuorescence detection, cells were transfected in Sonicseal
(Lab-TEK) wells with 200 ng of pECE-SOX10 and pCMVMyc-
SUMO1 per well.2.5. Immunoprecipitation assays
24 h post-transfection cells were scraped in PBS, pelleted and lysed
in 200 ll lysis buﬀer (5 mM Tris–HCl, pH 7.4, 150 mM NaCl, and
1% Triton X-100) plus complete protease inhibitors (Roche Applied
Sciences). The lysate was pre-cleared with Pansorbin cells (Calbio-
chem). After centrifugation a fraction of 10 ll of supernatant was con-
served for Western blot control. The remaining sample was incubated
with 1 lg of rabbit anti-HA antibody (Santa Cruz Biotechnology) or
mouse anti-Myc antibody (BD biosciences, Clontech) for 1 h at 4 C
with constant rotation. 20 ll of protein A/G was added and incubated
overnight. Samples were then washed three times with lysis buﬀer and
after centrifugation pellets were resuspended in ESB buﬀer (125 mM
Tris–HCL, pH 6.8, 5% SDS, 25% sucrose, and 5% b-mercap-
toethanol), heated at 80 C for 5 min and loaded on 10% SDS–poly-
acrylamide gels.
2.6. Western blot
After electrophoresis, proteins were electrotransfered onto PVDF
membranes (Amersham Biosciences). Proteins were immunodetected
by polyclonal or monoclonal antibodies followed by horseradish per-
oxidase (HRP)-conjugated anti-mouse or anti-rabbit immunoglobulin
G (IgG, Sigma Aldrich), and then visualised by chemiluminescence
with the ECL+ kit (Amersham Biosciences). Antibodies were used at
the following dilutions in blocking solution (PBS, 5% milk, 0.05%
Tween 20): anti-SOX10 (Chemicon International) 1:1000; mouse
anti-Myc 1:500; HRP-conjugated V5 antibody (Invitrogen) 1:5000.
2.7. Immunoﬂuorescence detection
24 h after transfection cells were ﬁxed 10 min in 4% paraformalde-
hyde and washed in PBS-T (PBS, 0.1% Triton X-100). Cells were incu-
bated with primary antibody (SOX10 1:200) diluted in blocking
solution (PBS-T, 1% BSA, 0.15% glycin) overnight at 4 C and then
for one hour at room temperature with Cy3-conjugated anti-rabbit sec-
ondary antibody (Sigma, 1:150) diluted in blocking solution. Cells
were mounted in Vectashield medium containing DAPI (Vector Labo-
ratories) and ﬂuorescence images were examined with a Leica DMR
epiﬂuorescence microscope.
2.8. Luciferase assays
Conditions for luciferase assays were previously described [8,9]. Re-
sults of luciferase activity assay were normalised by measuring total
amount of proteins in 25 ll of extracts with Coomassie Plus Protein
Assay Reagent Kit (Pierce Biotechnology).
2.9. Electrophoretic mobility shift assay
EMSA were performed as previously described on the S1S2 probe
[9] with nuclear extracts from HeLa cells expressing the MIC SOX10
mutant (E189X), MIC mutated at lysine 55, SOX-HA or SOX10-
HA mutated at its three sumoylated lysines.3. Results and discussion
3.1. SOX10 directly interacts with UBC9
While performing a two-hybrid screen using SOX10 deleted
from its transactivating domain as bait, we collected several
clones containing cDNAs corresponding to UBC9 coding se-
quence, suggesting direct interaction between the SOX10 and
UBC9 proteins.
We then performed co-immunoprecipitation experiments in
HeLa cells transfected with expression vectors allowing for
production of HA-tagged SOX10 and V5-tagged UBC9 pro-
teins. Upon precipitation of the SOX10 protein with anti-
HA antibody, Western blot detection revealed expression of
UBC9-V5 (25 kDa) in the sample (Fig. 1, lane 6), indicating
that UBC9 was co-immunoprecipitated with SOX10. This con-
ﬁrms direct interaction between both proteins.
As UBC9 is supposed to detect the sumoylation sequence on
the interacting protein [10], we searched for theWKXE sumoy-
lation consensus sequence in the SOX10 protein sequence. We
identiﬁed three potential sumoylation sites in the SOX10 pro-
tein that are conserved across evolution, as illustrated in
Fig. 2A. To determine the relative inﬂuence of these sumoyla-
tion sites on SOX10–UBC9 interaction, we mutated each site
individually or simultaneously in the SOX10 protein and per-
formed a liquid b-galactosidase activity measurement in yeast.
This allows a quantitative evaluation of the LacZ reporter
gene activation by the bait–prey interaction. The results de-
picted in Fig. 2B show that sites at positions K55 and K357
are each responsible for 50% of LacZ activation, and that acti-
vation is almost completely lost when both sites are mutated,
in a similar way as when the three sites are mutated. Conse-
quently, sites K55 and K357 mediate interaction between
SOX10 and UBC9 in yeast and may thus be involved in
SOX10 sumoylation in vivo.
3.2. SOX10 is SUMOylated
SOX10 interaction with UBC9 suggested that SOX10 may
be a target of sumoylation. To test this possibility, we used
an expression vector allowing for expression of a Myc-tagged
SUMO1 protein. When SOX10-HA, UBC9-V5 and/or Myc-
SUMO1 were co-transfected in HeLa cells, detection of
UBC9 expression revealed two bands, a 25 kDa band corre-
sponding to the tagged protein, and a band of higher molecu-
lar weight that may correspond to conjugation of an
endogenous SUMO peptide to the UBC9 protein (Fig. 3A,
lanes 2–3). Indeed, this species is represented in a higher pro-
portion when SUMO1 is transfected, indicating that it is actu-
ally a conjugated form of UBC9 and that overexpression of
SUMO1 mitigates the limitation in endogenous SUMO pep-
tide. When revealing SOX10 expression, we detected two
bands, one corresponding to native SOX10 protein (57 kDa),
the other one of higher molecular weight that may correspond
to attachment of a SUMO peptide to the SOX10 protein
(Fig. 3A, lane 3). This form disappears when the SOX10
protein carries mutations in the three potential sumoylation
sites (Fig. 3A, lane 4). To establish that this band is indeed
a sumoylated species of SOX10, we immunoprecipitated
sumoylated proteins with anti-Myc antibody and tested for
SOX10 and UBC9 expression (Fig. 3A, lanes 5–8). When
revealing UBC9 expression we detected only the conjugated
form of the protein (Fig. 3A, lanes 6–8), thus conﬁrming that
the Myc immunoprecipitation allows for precipitation of
Fig. 2. Sites K55 and K357 mediate SOX10–UBC9 interaction in yeast. (A) The three SOX10 sumoylation sites (underlined) are conserved across
evolution in vertebrates. The lysines of SUMO attachment are indicated in bold. (B) Relative b-galactosidase activity was calculated for each bait–
prey interaction between UBC9 and wild-type (wt) or mutant (mut) SOX10 baits. Mutant baits carry mutations in 1, 2 or 3 of the sumoylation sites as
indicated. The percentage of conserved b-galactosidase activity as compared with wild-type bait is indicated for each mutant bait in the table.
Fig. 1. SOX10 directly interacts with UBC9. SOX10 and UBC9 expression is detected by Western blot (WB) on crude lysates (lanes 1–3) or
immunoprecipitation (IP) samples (lanes 4–6) from HeLa cells expressing SOX10-HA and/or UBC9-V5. The upper part of the blot was revealed by
an anti-SOX10 antibody, the lower part with an anti-V5 antibody directed against UBC9 tag. The ladder on the side indicates positions and
molecular weights in kDa of marker proteins.
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sion, we detected the same two bands as observed on crude ly-
sates (Fig. 3A, lane 7), thus demonstrating that the high
molecular weight form indeed corresponds to attachment of
a SUMO peptide to the SOX10 protein. It is worth noting that
the non-sumoylated SOX10 protein was also co-precipitated in
this experiment. It may have been precipitated due to its inter-
action either with UBC9-SUMO during the conjugation pro-cess, or with other sumoylated proteins, including SOX10
itself. However, when the mutated SOX10 protein was ex-
pressed, SOX10 expression was no longer detected after
SUMO precipitation, thus conﬁrming that this protein is not
sumoylated (Fig. 3A, lane 8).
SOX10 sumoylation was conﬁrmed by the opposite experi-
ment, where we immunoprecipitated SOX10 and revealed
SUMO expression. We observed the same band at a higher
Fig. 3. SOX10 is SUMOylated. HeLa cells were transfected with wild-type or mutant SOX10-HA, UBC9-V5 and/or Myc-SUMO-1, -2 or -3 as
indicated. (A) SOX10 and UBC9 expression is detected as described in Fig. 1 on crude lysates (lanes 1–4) or immunoprecipitation samples (IP Myc,
lanes 5–8). (B) SUMO expression is detected by an anti-Myc antibody (WB Myc) after immunoprecipitation of SOX10 by an anti-HA antibody (IP
HA).
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the SOX10 protein (Fig. 3B, lanes 1–3). Furthermore, the same
experiment showed that SOX10 can be sumoylated by the
three SUMO proteins (1, 2, 3) of ubiquitous expression. It is
of note that sumoylation was not tested on endogenous
SOX10 protein in a cell line constitutively expressing SOX10
because a very high rate of expression is needed to detect the
sumoylated species, which can be achieved only through
expression in transfected cells. Indeed it is striking to observe
the relatively low proportion of the SOX10 sumoylated form
as compared with the unmodiﬁed form, suggesting a minor
representation of the sumoylated species in the cell. Alternately
this could be attributed to the protocol that may induce a par-
tial loss of the sumoylated form by cleavage of the SUMO
modiﬁcator, however it is likely that the modiﬁed species re-
mains a minority in the cell.
3.3. Functional consequences of SOX10 sumoylation
One of the functions attributed to sumoylation is regulation
of sub-cellular localisation of its substrate proteins [11]. How-
ever, mutating the three SOX10 potential sumoylation sites af-
fected neither its cellular localisation, nor its nuclear proﬁle as
compared with wild-type protein (Fig. 4A). SOX10 sumoyla-
tion is thus not required for SOX10 targeting to the nucleus.
Although SOX10 global distribution is mainly nuclear, it is de-scribed that it can shuttle between the cytoplasm and the nu-
cleus, and that this shuttling is mandatory for its
transcriptional activity [12]. This is of particular interest as
accumulating evidence suggests that sumoylation and nucleo-
cytoplasmic transport are interdependent processes [13]. Thus,
it may be possible that SUMO modiﬁcation is involved in
SOX10 nuclear export. This may be tested with heterokaryons
experiments as performed by Rehberg et al. [12].
To assess the inﬂuence of sumoylation on SOX10 ability to
bind DNA, we performed electrophoretic mobility shift assays.
These assays were realised on the one hand with the MIC
SOX10 mutant (E189X), which produces a truncated form
of the SOX10 protein and is usually used for SOX10 DNA
binding tests [9], and on the other hand with the HA-tagged
version of SOX10. In each case the wild-type and sumoylation
mutant proteins were tested. As presented in Fig. 4B, despite
the fact that the MIC form mutated in the K55 sumoylation
site appears to have an increased aﬃnity for DNA, the full
length protein mutated in the three sumoylation sites have
the same aﬃnity as wild-type protein, thus implying that
sumoylation does not aﬀect full length SOX10 DNA binding
properties.
Sumoylation is involved in the regulation of function of
many transcription factors [7], in most cases by reducing their
transcriptional capacities [6]. We thus tested the consequences
Fig. 4. SUMOylation is not required for SOX10 nuclear localisation and DNA binding. (A) SOX10 expression is detected in red and DAPI
ﬂuorescence reveals nuclei in blue in HeLa cells transfected with Myc-SUMO1 and wild-type or mutant SOX10 expression vectors. (B) EMSA were
performed with nuclear extracts from HeLa cells expressing a truncated (MIC) or full length SOX10 protein, wild-type or mutated in the sumoylation
sites. HMG = DNA-binding domain; TA = transactivation domain.
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aim, we tested the eﬀect of mutating the three sumoylation
sites on its activation of two of its target genes, GJB1 and
MITF. GJB1 encodes connexin32 (Cx32), a gap junction pro-
tein expressed by Schwann cells of the peripheral nervous sys-
tem. SOX10 regulates its expression by directly binding to its
promoter on a dimeric conﬁguration and in synergy with its
cofactor EGR2 [9]. MITF is a transcription factor essential
for melanocytes development and diﬀerentiation. Its expres-
sion is regulated by SOX10 binding to its promoter in a mono-
meric fashion and in synergy with its cofactor PAX3 [8]. We
performed luciferase assays in HeLa cells by cotransfecting
the GJB1 or MITF promoter with wild type and mutant
SOX10. We ﬁrst tested SOX10 autonomous transcriptional
activation of the GJB1 and MITF promoters. In both cases,
we observed that mutation of some sumoylation sites increased
SOX10 activation of the promoters, the maximum increase in
promoter activation being observed when all three sites are
mutated (Fig. 5A), thus indicating that all are inﬂuencing
SOX10 function. However, we observed some diﬀerences be-
tween the two promoters, suggesting that the impact of sumoy-
lation on SOX10 transactivating function diﬀers depending on
the target promoter, GJB1 orMITF. Accordingly, SOX10 reg-
ulates the GJB1 promoter activity through dimeric binding to
its DNA sequences, whereas it binds the MITF promoter only
as a monomer. The impact of sumoylation may thus not be
equivalent depending on SOX10 conformation on the regu-
lated promoter.
It should be noted that our Western blot experiments re-
vealed only one retarded form corresponding to attachment
of one SUMO peptide to the SOX10 protein, while our lucif-
erase assays suggest that all three sumoylation sites are func-
tional and may thus support attachment of several SUMO
peptides to the protein. It is therefore plausible that several
SUMO peptides can be attached to the SOX10 protein, how-
ever we were not able to detect this species due to its poor rep-
resentation in the cell. Accordingly several SOX10 sumoylatedspecies were observed in another study demonstrating SOX10
sumoylation in Xenopus [14].
Sumoylation is supposed to alter protein–protein interac-
tions, particularly in transcriptional complexes [7]. Conse-
quently, we next tested whether SOX10 sumoylation might
alter its interaction with two of its known cofactors EGR2
and PAX3, which are transcription factors that act in synergy
with SOX10 to activate the GJB1 and MITF promoters,
respectively. Mutation of one or several SOX10 sumoylation
sites signiﬁcantly increased the synergic activation of the
GJB1 and MITF promoters by SOX10 and its cofactors, with-
out aﬀecting individual activities of EGR2 and PAX3 on the
promoters (Fig. 5B and data not shown). This suggests that re-
peal of SOX10 sumoylation supports its transcriptional coop-
eration with its cofactors EGR2 and PAX3 on its target
promoters. In both cases mutation of one or two sites gener-
ated the same increase in promoter activation. Yet, maximum
activation is observed when all three sites are mutated, indicat-
ing that they are all involved in this cooperation.
In conclusion it appears that sumoylation represses both
SOX10 autonomous and synergistic transcriptional activation
of the GJB1 and MITF promoters.
It is worth noting that lysines are sites for various types of
post-translational modiﬁcation, including acetylation and
ubiquitination [15]. These modiﬁcations are not mutually
exclusive, thus it is possible that the eﬀects we observed while
mutating the lysines in the SOX10 protein might be due to dis-
tinct mechanisms. To address this point, we reproduced the
luciferase test on the GJB1 promoter with increasing amounts
of SUMO1 being transfected with wild-type or mutant SOX10.
As presented in Fig. 5C, addition of SUMO1 strongly reduced
wild-type SOX10 transcriptional activity on this promoter,
demonstrating that SOX10 function is indeed sensitive to
sumoylation. Conversely, mutant SOX10 activity was not sig-
niﬁcantly aﬀected by overexpression of SUMO1, thus demon-
strating that sumoylation is impaired on this mutant. Wild-
type SOX10 activity was reduced proportionally to the amount
Fig. 5. SUMOylation represses SOX10 transactivating function. (A) Autonomous transactivating activity of SOX10 proteins carrying mutations in
1, 2 or 3 sumoylation sites as indicated was tested on target promoters GJB1 and MITF. Fold induction of promoter activity is estimated by
calculating the ratio between luciferase activities with versus without the transcription factors. (B) Synergistic cooperation of mutant SOX10 proteins
with the EGR2 and PAX3 cofactors was compared with wild-type protein on target promoters GJB1 and MITF, respectively. Results are presented
as percentage of activity. (C) Transactivating activity of wild-type and mut 3K SOX10 protein was tested with increasing levels of SUMO1
expression. (D) Control of expression of SOX10 proteins in luciferase assays.
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dependent on the level of sumoylation in the cell.
Several SOX proteins were recently shown to be sumoylated,
suggesting this mechanism may be a more generally spread
phenomenon in the SOX proteins family [16,17]. Particularly,
sumoylation of SoxE factors, including Sox10, was recently
shown in Xenopus in an elegant study demonstrating that
sumoylation mediates a subset of the diverse activities charac-
teristic of SoxE proteins [14].
Similarly, MITF, which is involved in Waardenburg syn-
drome type II (WS2), is sumoylated [18,19] and PAX3, which
is involved in WS1 and WS3, contains several potentialsumoylation sites. Furthermore, MITF and PAX3 are also
SOX10 interacting partners. It is interesting to note that sev-
eral factors involved in the same regulation pathways and
pathological processes are subjected to the same mechanism
of regulation, thus suggesting that impairment of this process
may have functional consequences leading to pathophysiolog-
ical defects.
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